Grifols S.A. released a “Customer Alert” to apprise the community of steps the
pharmaceutical company has implemented to protect the integrity and security of its drug
products. It is cracking down on unauthorized channels of distribution that might
compromise the safety of Grifols’ drugs.

These steps include: placing restrictions on the acquisition and resale of Grifols products;
making public an authorized distributor list; mailing out “on-notice” letters to
unauthorized distributors; and improving distributor reporting and inspection
requirements.

Grifols manufactures several products used to treat patients with bleeding disorders.
Alphanate® is a plasma-derived factor concentrate for preventing and controlling
bleeding in patients with hemophilia A or acquired Factor VIII deficiency. AlphaNine®
is a plasma-derived factor concentrate for preventing and controlling bleeding in patients
with hemophilia B. Profilnine® is a plasma-derived factor concentrate for patients with
either factors II, VII or X deficiency.

Source: Grifols Customer Alert, April 2006